Last reviewed 2026-05-28 · How we verify

volatile agent only during reperfusion

University Medical Center Groningen · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

volatile agent only during reperfusion is a Small molecule drug developed by University Medical Center Groningen. It is currently in Phase 1 development.

Volatile agents have been studied in the context of kidney donation and transplantation, specifically in the VAPOR-1 trial, which investigated their use during reperfusion. The VAPOR-1 trial compared the effects of volatile agents to propofol in patients undergoing kidney transplantation.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	volatile agent only during reperfusion
Sponsor	University Medical Center Groningen
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

volatile agent only during reperfusion CI brief — competitive landscape report
volatile agent only during reperfusion updates RSS · CI watch RSS
University Medical Center Groningen portfolio CI

Frequently asked questions about volatile agent only during reperfusion

What is volatile agent only during reperfusion?

volatile agent only during reperfusion is a Small molecule drug developed by University Medical Center Groningen.

Who makes volatile agent only during reperfusion?

volatile agent only during reperfusion is developed by University Medical Center Groningen (see full University Medical Center Groningen pipeline at /company/university-medical-center-groningen).

What development phase is volatile agent only during reperfusion in?

volatile agent only during reperfusion is in Phase 1.

Manufacturer: University Medical Center Groningen — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing